| Homo sapiens |
MTD |
= |
200.0 |
mg |
Toxicity in healthy human administered bid up to 7 days |
CHEMBL2216751 |
| Homo sapiens |
MTD |
= |
400.0 |
mg |
Toxicity in healthy human |
CHEMBL2216751 |
| Homo sapiens |
Activity |
= |
56.0 |
% |
Antitumor activity in Non-Hodgkin Lymphoma patient assessed as clinical response rate at 50 to 350 mg, bid |
CHEMBL2216751 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
6.1 |
nM |
Inhibition of PI3Kdelta in B-cells by proliferation assay |
CHEMBL2216751 |
| Unchecked |
Ratio IC50 |
= |
49.0 |
|
Selectivity ratio of IC50 for PI3Kbeta to IC50 for PI3Kdelta |
CHEMBL2216751 |
| Unchecked |
Ratio IC50 |
= |
248.0 |
|
Selectivity ratio of IC50 for PI3Kalpha to IC50 for PI3Kdelta |
CHEMBL2216751 |
| Unchecked |
Ratio IC50 |
= |
21.0 |
|
Selectivity ratio of IC50 for PI3Kgamma to IC50 for PI3Kdelta |
CHEMBL2216751 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
9.0 |
nM |
Inhibition of PI3Kdelta |
CHEMBL2216751 |
| Unchecked |
Ratio IC50 |
= |
36.0 |
|
Selectivity ratio of IC50 for PI3Kgamma (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL2321770 |
| Unchecked |
Ratio IC50 |
= |
225.0 |
|
Selectivity ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL2321770 |
| Unchecked |
Ratio IC50 |
= |
328.0 |
|
Selectivity ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL2321770 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of PI3K p110gamma (unknown origin) |
CHEMBL2321770 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3K p110delta (unknown origin) |
CHEMBL2321770 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
562.0 |
nM |
Inhibition of PI3K p110beta (unknown origin) |
CHEMBL2321770 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of PI3K p110alpha (unknown origin) |
CHEMBL2321770 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL3217752 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) |
CHEMBL3217752 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
565.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) |
CHEMBL3217752 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) |
CHEMBL3217752 |
| Serine/threonine-protein kinase mTOR |
IC50 |
> |
10000.0 |
nM |
Inhibition of mTOR (unknown origin) |
CHEMBL3217752 |
| Unchecked |
IC50 |
> |
10000.0 |
nM |
Inhibition of PIP5K (unknown origin) |
CHEMBL3217752 |
| ADMET |
CL |
|
5.25 |
uL.min-1.(10^6cells)-1 |
ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736. |
CHEMBL3301361 |
| ADMET |
PPB |
|
81.01 |
% |
ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole mouse plasma at 37C for >5hrs. Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound. |
CHEMBL3301361 |
| ADMET |
CL |
|
19.5 |
uL.min-1.(10^6cells)-1 |
ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736 |
CHEMBL3301361 |
| No relevant target |
LogD7.4 |
|
2.72 |
|
ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5 |
CHEMBL3301361 |
| ADMET |
CL |
|
21.88 |
mL.min-1.g-1 |
ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736. |
CHEMBL3301361 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide |
IC50 |
> |
1000.0 |
nM |
Inhibition of human PI3KC2beta by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit alpha |
IC50 |
|
|
|
Inhibition of human PI3KC2alpha by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit gamma |
IC50 |
|
|
|
Inhibition of human PI3KC2gamma by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| Unchecked |
IC50 |
= |
978000.0 |
nM |
Inhibition of human class 3 PI3K by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
25.0 |
nM |
Inhibition of human PI3KCdelta by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| DNA-dependent protein kinase |
IC50 |
= |
6700.0 |
nM |
Inhibition of human DNA-PK by non-radiometric ADP-Glo assay |
CHEMBL3352433 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
9700.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) by biochemical Alphascreen assay |
CHEMBL3400094 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.7 |
nM |
Inhibition of PI3Kdelta (unknown origin) assessed as inhibition of AKT phosphorylation by cell-based HTRF assay |
CHEMBL3400094 |
| Pregnane X receptor |
Activity |
= |
3.7 |
% |
Activation of human PXR at 2 uM relative to rifampicin |
CHEMBL3400094 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
24.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) by biochemical Alphascreen assay |
CHEMBL3400094 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
580.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) by biochemical Alphascreen assay |
CHEMBL3400094 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
1400.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) by biochemical Alphascreen assay |
CHEMBL3400094 |
| Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform |
IC50 |
= |
579.0 |
nM |
Inhibition of human PI3K p110beta/p85beta by fluorescence-based immunoassay |
CHEMBL3769326 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
92.0 |
nM |
Inhibition of human PI3K 110gamma by fluorescence-based immunoassay |
CHEMBL3769326 |
| A549 |
IC50 |
= |
330.0 |
nM |
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay |
CHEMBL3769326 |
| HepG2 |
IC50 |
= |
920.0 |
nM |
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay |
CHEMBL3769326 |
| MCF7 |
IC50 |
= |
780.0 |
nM |
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay |
CHEMBL3769326 |
| HeLa |
IC50 |
= |
150.0 |
nM |
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay |
CHEMBL3769326 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
3.0 |
nM |
Inhibition of human PI3Kdelta by fluorescence-based immunoassay |
CHEMBL3769326 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
825.0 |
nM |
Inhibition of human PI3K p110alpha/p85alpha by fluorescence-based immunoassay |
CHEMBL3769326 |
| NON-PROTEIN TARGET |
IC50 |
= |
8400.0 |
nM |
Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| NON-PROTEIN TARGET |
IC50 |
= |
7900.0 |
nM |
Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| NON-PROTEIN TARGET |
IC50 |
= |
6300.0 |
nM |
Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| NON-PROTEIN TARGET |
IC50 |
= |
10600.0 |
nM |
Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| NON-PROTEIN TARGET |
IC50 |
= |
3600.0 |
nM |
Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
64.0 |
nM |
Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay |
CHEMBL3853357 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.0 |
nM |
Inhibition of human PI3Kdelta (R108 to Q1044 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay |
CHEMBL3853357 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of p110delta in HMEC assessed as reduction in S6RP phosphorylation at Ser-235/236 residue at 10 nM after 1 hr by Western blot analysis |
CHEMBL3853357 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of p110delta in HMEC assessed as reduction in Akt phosphorylation at Thr-308 residue at 10 nM after 1 hr by Western blot analysis |
CHEMBL3853357 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of p110delta in HMEC assessed as reduction in Akt phosphorylation at Ser-473 residue at 10 nM after 1 hr by Western blot analysis |
CHEMBL3853357 |
| NON-PROTEIN TARGET |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against patient-derived IgM-stimulated CLL cells after 3 days by CellTiter-Glo assay |
CHEMBL3853357 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide |
IC50 |
> |
1000.0 |
nM |
Inhibition of human recombinant PI3KC2beta by Select-screen kinase inhibitor assay |
CHEMBL3860068 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
25.0 |
nM |
Inhibition of his-tagged human recombinant PIK3CD/PIK3R1 by Select-screen kinase inhibitor assay |
CHEMBL3860068 |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 |
IC50 |
= |
978000.0 |
nM |
Inhibition of human recombinant Vps34 by Select-screen kinase inhibitor assay |
CHEMBL3860068 |
| DNA-dependent protein kinase |
IC50 |
= |
6700.0 |
nM |
Inhibition of human recombinant DNA-PK by Select-screen kinase inhibitor assay |
CHEMBL3860068 |
| NON-PROTEIN TARGET |
IC50 |
= |
100.0 |
nM |
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/cytochalasin B-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c preincubated for 5 mins followed by FMLP/cytochalasin B-induction by spectrophotometric analysis |
CHEMBL3865837 |
| NON-PROTEIN TARGET |
IC50 |
= |
300.0 |
nM |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as elastase substrate preincubated for 5 mins followed by fMLP/CB-induction |
CHEMBL3865837 |
| NON-PROTEIN TARGET |
Inhibition |
= |
103.0 |
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c at 10 uM preincubated for 5 mins followed by fMLP/CB-induction measured after 10 mins |
CHEMBL3867445 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase-inhibitable reduction of ferricytochrome c at 20 uM preincubated for 5 mins followed by fMLP/CB-induction measured after 10 mins |
CHEMBL3867445 |
| NON-PROTEIN TARGET |
Inhibition |
= |
100.0 |
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release at 10 uM using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as elastase substrate preincubated for 5 mins followed by fMLP/CB-induction |
CHEMBL3867445 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release at 20 uM using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as elastase substrate preincubated for 5 mins followed by fMLP/CB-induction |
CHEMBL3867445 |
| ADMET |
Drug metabolism |
= |
20.0 |
% |
Drug metabolism in rat liver microsomes assessed as disappearance of parent compound at 5 uM after 30 mins in presence of NADPH by UPLC-MS/MS analysis |
CHEMBL3872285 |
| ADMET |
Drug metabolism |
= |
21.0 |
% |
Drug metabolism in human liver microsomes assessed as disappearance of parent compound at 5 uM after 30 mins in presence of NADPH by UPLC-MS/MS analysis |
CHEMBL3872285 |
| ADMET |
T1/2 |
= |
0.8 |
hr |
Half life in Wistar rat at 1 mg/kg, iv |
CHEMBL3872285 |
| ADMET |
AUC |
= |
512.0 |
ng.hr.mL-1 |
AUC in Wistar rat at 1 mg/kg, iv |
CHEMBL3872285 |
| ADMET |
CL |
= |
32.8 |
mL.min-1.kg-1 |
Clearance in Wistar rat at 1 mg/kg, iv |
CHEMBL3872285 |
| ADMET |
F |
= |
68.0 |
% |
Oral bioavailability in Wistar rat at 1 mg/kg administered via gavage |
CHEMBL3872285 |
| Rattus norvegicus |
ID50 |
= |
1.6 |
mg.kg-1 |
In vivo inhibition of PI3Kdelta in Wistar rat assessed as reduction in ConA-induced increase in plasma IL2 production administered through oral gavage 1 hr prior to ConA measured 90 mins post ConA challenge by ELISA |
CHEMBL3872285 |
| NON-PROTEIN TARGET |
ID50 |
= |
15.0 |
mg.kg-1 |
Anti-inflammatory activity in Brown Norway rat assessed as reduction in OVA-induced eosinophil infilteration to bronchoalveolar lavage administered orally bid 1 hr prior to OVA challenge on day 14 and 6 hrs post OVA challenge on day 21 measured 24 hrs post last OVA challenge by microscopic method |
CHEMBL3872285 |
| ADMET |
T1/2 |
= |
1.6 |
hr |
Half life in Beagle dog at 1 mg/kg, iv through bolus administration |
CHEMBL3872285 |
| ADMET |
AUC |
= |
924.0 |
ng.hr.mL-1 |
AUC in Beagle dog at 1 mg/kg, iv through bolus administration |
CHEMBL3872285 |
| ADMET |
CL |
= |
21.5 |
mL.min-1.kg-1 |
Clearance in Beagle dog at 1 mg/kg, iv through bolus administration |
CHEMBL3872285 |
| NON-PROTEIN TARGET |
Vd |
= |
2.5 |
L.kg-1 |
Apparent volume of distribution in Beagle dog at 1 mg/kg, iv through bolus administration |
CHEMBL3872285 |
| NON-PROTEIN TARGET |
Vd |
= |
2.2 |
L.kg-1 |
Apparent volume of distribution in Wistar rat at 1 mg/kg, iv |
CHEMBL3872285 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
9.0 |
nM |
Biochemical Assays: Compounds of the invention were tested for inhibitory activity and potency against PI3Kδ. |
CHEMBL3638730 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
9.0 |
nM |
Biochemical Assay: Using the method described in Example 2, compounds of the invention were tested for inhibitory activity and potency against PI3Kdelta, and for selectivity for PI3Kdelta versus other Class I PI3K isozymes. In Table 1, IC50 values (uM) are given for PI3Kdelta (Delta), and may be calculated for the other isoforms using the ratios of IC50 values discussed below. To illustrate selectivity of the compounds, the ratios of the IC50 values of the compounds for PI3Kalpha, PI3Kbeta, and PI3Kgamma relative to PI3Kdelta are given, respectively, as Alpha/Delta Ratio, Beta/Delta Ratio, and Gamma/Delta Ratio.The initial selectivity assays were performed identically to the selectivity assay protocol in Example 2, except, using 100 uL Ecosint for radiolabel detection. Subsequent selectivity assays were done similarly using the same 3 substrate stocks except they contained 0.05 mCi/mL gamma [32P] ATP and 3 mM PIP2. Subsequent selectivity assays also used the same 3 enzyme stocks. |
CHEMBL3639252 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
9.0 |
nM |
Biochemical Assay: Using the method described in US9149477, Example 2, compounds of the invention were tested for inhibitory activity and potency against PI3Kδ, and for selectivity for PI3Kδ versus other Class I PI3K isozymes. The initial selectivity assays were performed identically to the selectivity assay protocol in US9149477, Example 2, except using 100 μL Ecoscint for radiolabel detection. Subsequent selectivity assays were done similarly using the same 3× substrate stocks except they contained 0.05 mCi/mL γ[32P]ATP and 3 mM PIP2. Subsequent selectivity assays also used the same 3× enzyme stocks, except they now contained 3 nM of any given PI3K isoform. |
CHEMBL3886270 |
| Adaptor-associated kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase ABL |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase ABL2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Acyl-CoA dehydrogenase family member 10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Acyl-CoA dehydrogenase family member 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Peroxisomal acyl-coenzyme A oxidase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Peroxisomal acyl-coenzyme A oxidase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Long-chain-fatty-acid--CoA ligase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Actin-related protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Actin-related protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-1B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Activin receptor type-2B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Uncharacterized aarF domain-containing protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Chaperone activity of bc1 complex-like, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Uncharacterized aarF domain-containing protein kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenosine kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| G-protein coupled receptor kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenylate kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase AKT3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Adenine phosphoribosyltransferase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase A-Raf |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine-protein kinase ATR |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Aurora-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Aurora-B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Breakpoint cluster region protein |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| BMP-2-inducible protein kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-1A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-1B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Bone morphogenetic protein receptor type-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase B-raf |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase BTK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitotic checkpoint serine/threonine-protein kinase BUB1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase II delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase II gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM kinase IV |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| CaM-kinase kinase beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cysteine--tRNA ligase, cytoplasmic |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MRCK gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 12 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 13 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PCTAIRE-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PCTAIRE-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase 9 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cyclin-dependent kinase-like 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Chromodomain-helicase-DNA-binding protein 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Chk1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Citron Rho-interacting kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificty protein kinase CLK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity protein kinase CLK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity protein kinase CLK4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase CSK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I epsilon |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I gamma 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I gamma 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase I isoform gamma-3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Casein kinase II alpha (prime) |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Cytochrome c1, heme protein, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Deoxycytidine kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| dCTP pyrophosphatase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Epithelial discoidin domain-containing receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Discoidin domain-containing receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX3X |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DDX42 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Probable ATP-dependent RNA helicase DDX6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Delta(24)-sterol reductase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ATP-dependent RNA helicase DHX30 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DnaJ homolog subfamily A member 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual-specificity tyrosine-phosphorylation regulated kinase 1A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Epidermal growth factor receptor erbB1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Eukaryotic translation initiation factor 5B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-A receptor 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ephrin type-B receptor 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| General transcription and DNA repair factor IIH helicase subunit XPD |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Electron transfer flavoprotein subunit beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phenylalanine--tRNA ligase beta subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ferrochelatase, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FER |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FES |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Fibroblast growth factor receptor 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FGR |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase receptor FLT3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FRK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase FYN |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase GAK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycine--tRNA ligase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Guanine nucleotide-binding protein G(i) subunit alpha-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| G protein-coupled receptor kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycogen synthase kinase-3 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Glycogen synthase kinase-3 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Nucleolar GTP-binding protein 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase HCK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Heme oxygenase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Putative heat shock protein HSP 90-beta 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ICK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Insulin-like growth factor I receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Inhibitor of nuclear factor kappa B kinase epsilon subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ILK-1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Inosine-5'-monophosphate dehydrogenase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Insulin receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Interleukin-1 receptor-associated kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase JAK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase LATS1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase LCK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| LIM domain kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| LIM domain kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase Lyn |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity mitogen-activated protein kinase kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase kinase kinase kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase ERK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase p38 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase p38 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase 15 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase ERK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mitogen-activated protein kinase 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| c-Jun N-terminal kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase-activated protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase-activated protein kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP kinase-activated protein kinase 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP/microtubule affinity-regulating kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase c-TAK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| MAP/microtubule affinity-regulating kinase 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| S-adenosylmethionine synthase isoform type-2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA replication licensing factor MCM4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Midasin |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Maternal embryonic leucine zipper kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Hepatocyte growth factor receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Misshapen-like kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Macrophage-stimulating protein receptor |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin light chain kinase, smooth muscle |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Myosin light chain kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| RNA cytidine acetyltransferase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Nek1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase NEK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase Nek3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase NEK9 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine protein kinase NLK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Quinone reductase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Nerve growth factor receptor Trk-A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| NUAK family SNF1-like kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dynamin-like 120 kDa protein, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Multifunctional protein ADE2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PAK 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PAK 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PAK6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| PAS domain-containing serine/threonine-protein kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Platelet-derived growth factor receptor beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Pyridoxal kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylethanolamine-binding protein 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphofructokinase platelet type |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Membrane-associated progesterone receptor component 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphorylase kinase gamma subunit 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PIM1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Phosphatidylinositol-5-phosphate 4-kinase type-2 gamma |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine- and threonine-specific cdc2-inhibitory kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase N1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase N2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase N3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PLK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase PLK4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, alpha-1 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase alpha-catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase beta-1 catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase, gamma catalytic subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, gamma-1 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| AMP-activated protein kinase, gamma-2 subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C delta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C iota |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C theta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase D2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein kinase C nu |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| cGMP-dependent protein kinase 1 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Unchecked |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| 26S protease regulatory subunit 6B |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Focal adhesion kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Protein tyrosine kinase 2 beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase BRK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Brain glycogen phosphorylase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Liver glycogen phosphorylase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Uncharacterized protein FLJ45252 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ras-related protein Rab-10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ras-related protein Rab-27A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ras-related protein Rab-6A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rab-like protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| GTP-binding nuclear protein Ran |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase receptor RET |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase RIPK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Receptor-interacting serine/threonine-protein kinase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rho-associated protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Rho-associated protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 5 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase alpha 6 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Ribosomal protein S6 kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Septin-9 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase SIK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase SIK3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Exosome RNA helicase MTR4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ADP/ATP translocase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| ADP/ATP translocase 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Structural maintenance of chromosomes protein 1A |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Structural maintenance of chromosomes protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase SRC |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Signal recognition particle receptor subunit alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 10 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 11 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 16 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 24 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST4 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 38 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase 38-like |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase MST1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| STE20-related kinase adapter protein alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase SYK |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TAO3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase TBK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase TEC |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity testis-specific protein kinase 1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Dual specificity testis-specific protein kinase 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TGF-beta receptor type I |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TGF-beta receptor type II |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Thyroid hormone receptor-associated protein 3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TRAF2- and NCK-interacting kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Non-receptor tyrosine-protein kinase TNK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine kinase non-receptor protein 2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA topoisomerase II alpha |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| DNA topoisomerase II beta |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| TP53-regulating kinase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Elongation factor Tu, mitochondrial |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase TYK2 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ULK1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase ULK3 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Serine/threonine-protein kinase WEE1 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosyl-tRNA synthetase |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Tyrosine-protein kinase YES |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| Mixed lineage kinase 7 |
Kd |
> |
30000.0 |
nM |
Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry. |
CHEMBL3991601 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
7500.0 |
nM |
Inhibition of human full length PI3K p110alpha/p85 alpha using PIP2/ATP as substrate after 30 mins by TR-FRET assay |
CHEMBL4004819 |
| PI3K p110 beta/p85 alpha |
IC50 |
= |
3700.0 |
nM |
Inhibition of N-terminal His6-tagged recombinant full-length human PI3K p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2/ATP as substrate after 30 mins by TR-FRET assay |
CHEMBL4004819 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
18.0 |
nM |
Inhibition of human full length PI3K p110delta/p85 alpha using PIP2/ATP as substrate after 30 mins by TR-FRET assay |
CHEMBL4004819 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
2100.0 |
nM |
Inhibition of human full length PI3Kgamma using PIP2/ATP as substrate after 30 mins by TR-FRET assay |
CHEMBL4004819 |
| Unchecked |
Ratio IC50 |
= |
20.0 |
|
Selectivity ratio of IC50 for PI3Kgamma (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4014340 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL4014340 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
63.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) |
CHEMBL4014340 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
800.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) |
CHEMBL4014340 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
380.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) |
CHEMBL4014340 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay |
CHEMBL4024705 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
63.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay |
CHEMBL4024705 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
800.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay |
CHEMBL4024705 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
380.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) after 60 mins using fluorescein-labeled kinase tracer by HTRF assay |
CHEMBL4024705 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
4.3 |
nM |
Inhibition of PI3Kdelta (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay |
CHEMBL4041516 |
| SU-DHL-6 |
IC50 |
= |
117.6 |
nM |
Antiproliferative activity against human SUDHL6 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
1650.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay |
CHEMBL4041516 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
669.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay |
CHEMBL4041516 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
241.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate measured after 30 mins by HTRF assay |
CHEMBL4041516 |
| KARPAS-422 |
IC50 |
= |
8100.0 |
nM |
Antiproliferative activity against human KARPAS422 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| Unchecked |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human WSU-DLCL2 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| HT |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human HT cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| Pfeiffer |
IC50 |
= |
6800.0 |
nM |
Antiproliferative activity against human Pfeiffer cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| NAMALVA |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human NAMALWA cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| SU-DHL-1 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human SU-DHL1 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| SUD4 |
IC50 |
= |
1600.0 |
nM |
Antiproliferative activity against human SU-DHL4 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| SU-DHL10 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human SU-DHL10 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| MOLT-4 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human MOLT4 cells measured after 72 hrs by alamar blue assay |
CHEMBL4041516 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of human full length His-tagged PI3Kdelta expressed in baculovirus expression system |
CHEMBL4041516 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of recombinant human full length His-tagged PI3Kalpha expressed in baculovirus expression system |
CHEMBL4041516 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
565.0 |
nM |
Inhibition of recombinant human full length His-tagged PI3Kbeta expressed in insect cells |
CHEMBL4041516 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of recombinant human full length His-tagged PI3Kgamma expressed in insect cells |
CHEMBL4041516 |
| PI3-kinase p110-delta/p85-alpha |
Inhibition |
= |
96.0 |
% |
Inhibition of PI3K p110delta/p85alpha (unknown origin) at 100 nM using lipid substrate after 40 mins by kinase-glo luminescence assay relative to control |
CHEMBL4049417 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
2.7 |
nM |
Inhibition of PI3K p110delta/p85alpha (unknown origin) using lipid substrate after 40 mins by kinase-glo luminescence assay |
CHEMBL4049417 |
| Unchecked |
IC50 |
= |
5.49 |
nM |
Antiproliferative activity against human RPMI8266 cells after 72 hrs by MTT assay |
CHEMBL4049417 |
| Ramos |
IC50 |
> |
10.0 |
nM |
Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay |
CHEMBL4049417 |
| Raji |
IC50 |
= |
9.95 |
nM |
Antiproliferative activity against human Raji cells after 72 hrs by MTT assay |
CHEMBL4049417 |
| Unchecked |
IC50 |
= |
70.0 |
nM |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide oxide dismutase inhibitable reduction of ferricytochrome c incubated for 5 mins |
CHEMBL4052701 |
| Unchecked |
Inhibition |
= |
102.8 |
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide oxide dismutase inhibitable reduction of ferricytochrome c at 10 uM incubated for 5 mins |
CHEMBL4052701 |
| Unchecked |
IC50 |
= |
300.0 |
nM |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release incubated for 5 mins in presence of MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide |
CHEMBL4052701 |
| Unchecked |
Inhibition |
= |
99.6 |
% |
Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release at 10 uM incubated for 5 mins in presence of MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide |
CHEMBL4052701 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
391.3 |
nM |
Inhibition of PI3Kalpha (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 10 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
845.5 |
nM |
Inhibition of PI3Kbeta (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
67.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
5.9 |
nM |
Inhibition of PI3Kdelta (unknown origin) using PIP2:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit alpha |
IC50 |
> |
10000.0 |
nM |
Inhibition of N-terminal GST-tagged recombinant human PIK3C2A catalytic domain expressed in Baculovirus expression system using PI as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing beta polypeptide |
IC50 |
> |
10000.0 |
nM |
Inhibition of N-terminal GST-tagged recombinant human PIK3C2B catalytic domain expressed in Baculovirus expression system using PI as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 |
IC50 |
= |
4417.0 |
nM |
Inhibition of GST-tagged full length recombinant human VPS34 expressed in Baculovirus expression system using PI:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PI4-kinase alpha subunit |
IC50 |
> |
10000.0 |
nM |
Inhibition of PI4K3A (unknown origin) using PI:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PI4-kinase beta subunit |
IC50 |
> |
10000.0 |
nM |
Inhibition of PI4K3B (unknown origin) using PI:PS as substrate preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 50 uM ATP by ADP-Glo luminescence assay |
CHEMBL4152344 |
| PF-382 |
GI50 |
> |
10000.0 |
nM |
Growth inhibition of human PF382 cells after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4152344 |
| NALM-6 |
GI50 |
> |
10000.0 |
nM |
Growth inhibition of human NALM6 cells after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4152344 |
| MV4-11 |
GI50 |
> |
10000.0 |
nM |
Growth inhibition of human MV4-11 cells after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4152344 |
| MOLM-14 |
GI50 |
= |
6400.0 |
nM |
Growth inhibition of human MOLM14 cells after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4152344 |
| MOLM-13 |
GI50 |
= |
1700.0 |
nM |
Growth inhibition of human MOLM13 cells after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4152344 |
| MOLM-14 |
TGI |
|
|
|
Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as tumor growth inhibition at 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing relative to control |
CHEMBL4152344 |
| MOLM-14 |
Activity |
|
|
|
Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as induction of apoptosis at 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing by TUNEL based assay |
CHEMBL4152344 |
| MOLM-14 |
Activity |
|
|
|
Antitumor activity against human MOLM14 cells xenografted in nu/nu mouse assessed as inhibition of tumor proliferation 100 mg/kg, po administered daily via gavage dosed for 14 days and measured daily during compound dosing by Ki-67 labelling based immunohistochemical analysis |
CHEMBL4152344 |
| NCI-H460 |
GI50 |
|
|
|
Growth inhibition of human NCI-H460 cells after 72 hrs by SRB assay |
CHEMBL4190336 |
| MCF7 |
GI50 |
|
|
|
Growth inhibition of human MCF7 cells after 72 hrs by SRB assay |
CHEMBL4190336 |
| T47D |
GI50 |
|
|
|
Growth inhibition of human T47D cells after 72 hrs by SRB assay |
CHEMBL4190336 |
| U-87 MG |
GI50 |
|
|
|
Growth inhibition of human U87MG cells after 72 hrs by SRB assay |
CHEMBL4190336 |
| KARPAS-422 |
GI50 |
= |
680.0 |
nM |
Growth inhibition of human KARPAS422 cells by CCK8 assay |
CHEMBL4190336 |
| Pfeiffer |
GI50 |
= |
740.0 |
nM |
Growth inhibition of human Pfeiffer cells by CCK8 assay |
CHEMBL4190336 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of human recombinant PI3K-delta |
CHEMBL4219103 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
120.1 |
nM |
Inhibition of PI3K p110beta (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay |
CHEMBL4219144 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
306.4 |
nM |
Inhibition of PI3K p110alpha (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay |
CHEMBL4219144 |
| PI3-kinase p110-delta subunit |
Inhibition |
= |
96.0 |
% |
Inhibition of PI3K p110delta (unknown origin) at 100 nM using lipid substrate after 40 mins by kinase-Glo assay relative to control |
CHEMBL4219144 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.7 |
nM |
Inhibition of PI3K p110delta (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay |
CHEMBL4219144 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL4219144 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
139.4 |
nM |
Inhibition of PI3K p110gamma (unknown origin) using lipid substrate after 40 mins by kinase-Glo assay |
CHEMBL4219144 |
| Ramos |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human Ramos cells after 72 hrs by MTT assay |
CHEMBL4219144 |
| Raji |
IC50 |
= |
9950.0 |
nM |
Antiproliferative activity against human Raji cells after 72 hrs by MTT assay |
CHEMBL4219144 |
| RPMI-8226 |
IC50 |
= |
5490.0 |
nM |
Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay |
CHEMBL4219144 |
| SU-DHL-6 |
IC50 |
= |
650.0 |
nM |
Antiproliferative activity against human SUDHL6 cells after 72 hrs by CCK8 assay |
CHEMBL4219144 |
| Rattus norvegicus |
Cmax |
= |
310.52 |
nM |
Cmax in Sprague-Dawley rat at 3 mg/kg, po by LC-MS/MS analysis |
CHEMBL4219144 |
| Rattus norvegicus |
AUC |
= |
422.0 |
ng.hr.mL-1 |
AUC in Sprague-Dawley rat at 3 mg/kg, po by LC-MS/MS analysis |
CHEMBL4219144 |
| Rattus norvegicus |
T1/2 |
= |
1.52 |
hr |
Half life in Sprague-Dawley rat at 3 mg/kg, po by LC-MS/MS analysis |
CHEMBL4219144 |
| Rattus norvegicus |
F |
= |
39.0 |
% |
Oral bioavailability in Sprague-Dawley rat at 3 mg/kg by LC-MS/MS analysis |
CHEMBL4219144 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
1.6 |
nM |
Inhibition of PI3Kdelta (unknown origin) using Biotin-S11S12 as substrate after 120 mins in presence of ATP by ADPGlo luminescence assay |
CHEMBL4229370 |
| PI3-kinase p110-delta subunit |
Inhibition |
= |
91.91 |
% |
Inhibition of PI3Kdelta (unknown origin) at 1 uM using Biotin-S11S12 as substrate after 120 mins in presence of ATP by ADPGlo luminescence assay |
CHEMBL4229370 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
737.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by Kinase Glo luminescence assay |
CHEMBL4229370 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
129.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by ADPGlo luminescence assay |
CHEMBL4229370 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
139.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) using Biotin-S11S12 as substrate after 60 mins in presence of ATP by ADPGlo luminescence assay |
CHEMBL4229370 |
| Unchecked |
Ratio IC50 |
= |
460.0 |
|
Selectivity index, ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4229370 |
| Unchecked |
Ratio IC50 |
= |
80.0 |
|
Selectivity index, ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4229370 |
| Unchecked |
Ratio IC50 |
= |
86.0 |
|
Selectivity index, ratio of IC50 for PI3Kgamma (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4229370 |
| SU-DHL-6 |
GI50 |
= |
42.0 |
nM |
Growth inhibition of human SU-DHL6 cells by CellTiter-Glo assay |
CHEMBL4229370 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
2000.0 |
nM |
Inhibition of PI3KCalpha/PIK3R1 (unknown origin) |
CHEMBL4265934 |
| PI3K p110 beta/p85 alpha |
IC50 |
= |
600.0 |
nM |
Inhibition of PI3KCbeta/PIK3R1 (unknown origin) |
CHEMBL4265934 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
17.0 |
nM |
Inhibition of PI3KCdelta/PIK3R1 (unknown origin) |
CHEMBL4265934 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
250.0 |
nM |
Inhibition of PI3KCgamma (unknown origin) |
CHEMBL4265934 |
| SARS-CoV-2 |
Inhibition |
= |
-4.09 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| SARS-CoV-2 |
Hit score |
= |
0.4259 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| SARS-CoV-2 |
Hit score |
= |
-0.08519 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in Vero cells at MOI 0.08 after 48 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
583.0 |
nM |
Inhibition of PI3K alpha (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay |
CHEMBL4304761 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
134.0 |
nM |
Inhibition of PI3K beta (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay |
CHEMBL4304761 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
381.0 |
nM |
Inhibition of PI3K gamma (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay |
CHEMBL4304761 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
3.1 |
nM |
Inhibition of PI3K delta (unknown origin) using lipid substrate measured after 40 mins in presence of ATP by Kinase-Glo plus reagent based luminescence assay |
CHEMBL4304761 |
| Unchecked |
Ratio IC50 |
= |
33.0 |
|
Selectivity ratio of IC50 for inhibition of PI3K beta (unknown origin) to IC50 for inhibition of PI3K delta (unknown origin) |
CHEMBL4304761 |
| Unchecked |
Ratio IC50 |
> |
100.0 |
|
Selectivity ratio of IC50 for inhibition of PI3K alpha (unknown origin) to IC50 for inhibition of PI3K delta (unknown origin) |
CHEMBL4304761 |
| Unchecked |
Ratio IC50 |
> |
100.0 |
|
Selectivity ratio of IC50 for inhibition of PI3K gamma (unknown origin) to IC50 for inhibition of PI3K delta (unknown origin) |
CHEMBL4304761 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
19.0 |
nM |
Inhibition of PIK3CD (unknown origin) |
CHEMBL4321790 |
| Unchecked |
IC50 |
> |
20000.0 |
nM |
Antifibrotic activity against mouse Mlg2908 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay |
CHEMBL4321792 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL4330088 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
63.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) |
CHEMBL4330088 |
| PI3K p110 beta/p85 alpha |
IC50 |
= |
3807.0 |
nM |
Inhibition of human full length recombinant N-terminal His-tagged PI3Kbeta/p85alpha expressed in baculovirus infected Sf21 insect cells |
CHEMBL4330088 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
800.0 |
nM |
Inhibition of human N-terminal His-tagged PI3Kalpha/p85alpha expressed in Spodoptera frugiperda using phosphatidylinositol as substrate |
CHEMBL4330088 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3Kdelta in basophil derived from B-cell malignant patient |
CHEMBL4350952 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of PI3Kgamma in basophil derived from B-cell malignant patient |
CHEMBL4350952 |
| Unchecked |
Ratio IC50 |
= |
330.0 |
|
Selectivity ratio of IC50 for PI3Kalpha in basophil derived from B-cell malignant patient to IC50 for PI3Kdelta in basophil derived from B-cell malignant patient |
CHEMBL4350952 |
| Unchecked |
Ratio IC50 |
= |
230.0 |
|
Selectivity ratio of IC50 for PI3Kbeta in basophil derived from B-cell malignant patient to IC50 for PI3Kdelta in basophil derived from B-cell malignant patient |
CHEMBL4350952 |
| Unchecked |
IC50 |
= |
846.0 |
nM |
Cytotoxicity against basophil derived from B-cell malignant patient by cell-titer aqueous one solution cell proliferation assay |
CHEMBL4350952 |
| Phosphatidylinositol 3-kinase catalytic subunit type 3 |
IC50 |
= |
980.0 |
nM |
Inhibition of Vps34 (unknown origin) |
CHEMBL4350952 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
104.0 |
nM |
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay |
CHEMBL4350965 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
2.0 |
nM |
Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay |
CHEMBL4350965 |
| PI3K p110 beta/p85 alpha |
IC50 |
= |
293.0 |
nM |
Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay |
CHEMBL4350965 |
| PI3-kinase p110-gamma subunit |
Inhibition |
< |
50.0 |
% |
Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control |
CHEMBL4350965 |
| PI3-kinase p110-delta/p85-alpha |
Inhibition |
< |
50.0 |
% |
Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control |
CHEMBL4350965 |
| PI3K p110 beta/p85 alpha |
Inhibition |
< |
50.0 |
% |
Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control |
CHEMBL4350965 |
| Unchecked |
IC50 |
= |
337.0 |
nM |
Inhibition of PI3Kgamma in rat RAW264.7 cells assessed as reduction in C5a-stimulated AKT phosphorylation at Ser473 residue preincubated for 30 mins followed by C5a-stimulation and measured after 5 mins |
CHEMBL4350965 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
4.0 |
nM |
Inhibition of PI3Kdelta in human Ramos cells assessed as reduction in antihuman IgM-stimulated AKT phosphorylation at Ser473 residue preincubated for 60 mins followed by antihuman IgM stimulation and measured after 15 mins |
CHEMBL4350965 |
| ADMET |
Stability |
|
|
% |
Stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH generating system |
CHEMBL4350965 |
| ADMET |
Stability |
|
|
% |
Stability in human liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH generating system |
CHEMBL4350965 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
2100.0 |
nM |
Inhibition of His-tagged recombinant human PIK3CG expressed in Baculovirus expression system |
CHEMBL4354810 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
4000.0 |
nM |
Inhibition of His-tagged recombinant human PIK3CB |
CHEMBL4354810 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
8600.0 |
nM |
Inhibition of His-tagged recombinant human PIK3CA/PIK3R1 expressed in Baculovirus expression system |
CHEMBL4354810 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
19.0 |
nM |
Inhibition of His-tagged recombinant human PI3K p110delta/p85alpha expressed in Baculovirus expression system |
CHEMBL4354810 |
| Unchecked |
Ratio IC50 |
= |
19.0 |
|
Selectivity ratio of IC50 for PI3Kgamma (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4368891 |
| Unchecked |
Ratio IC50 |
= |
88.0 |
|
Selectivity ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4368891 |
| Unchecked |
Ratio IC50 |
= |
257.0 |
|
Selectivity ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4368891 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
60.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay |
CHEMBL4368891 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
281.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay |
CHEMBL4368891 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
822.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay |
CHEMBL4368891 |
| SU-DHL-6 |
GI50 |
= |
20.0 |
nM |
Antiproliferative activity against human SU-DHL6 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay |
CHEMBL4368891 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
3.2 |
nM |
Inhibition of PI3Kdelta (unknown origin) using PIP2 as substrate after 2 hrs by ADP-Glo assay |
CHEMBL4368891 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
1.8 |
nM |
Inhibition of His-tagged recombinant human PI3K p110delta/p85alpha using lipid substrate incubated for 2 hrs by ADP-Glo assay |
CHEMBL4385593 |
| SU-DHL-6 |
GI50 |
= |
124.0 |
nM |
Growth inhibition of human SU-DHL6 cells incubated for 72 hrs by CellTiter-Glo assay |
CHEMBL4385593 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
2164.0 |
nM |
Inhibition of His-tagged recombinant human full length PI3K p110alpha/p85alpha expressed in baculovirus expression system using lipid substrate incubated for 60 mins by kinase-Glo reagent based luminescence assay |
CHEMBL4385593 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
154.0 |
nM |
Inhibition of His6-tagged recombinant full length human N-terminal PI3Kbeta expressed in baculovirus infected Sf21 cells using lipid substrate incubated for 2 hrs by ADP-Glo assay |
CHEMBL4385593 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
63.0 |
nM |
Inhibition of His-tagged recombinant human full length PI3K p110gamma expressed in baculovirus expression system using lipid substrate incubated for 2 hrs by ADP-Glo assay |
CHEMBL4385593 |
| Unchecked |
Ratio IC50 |
= |
1202.0 |
|
Selectivity ratio of IC50 for His-tagged recombinant human full length PI3K p110alpha/p85alpha to IC50 for His-tagged recombinant human PI3K p110delta/p85alpha |
CHEMBL4385593 |
| Unchecked |
Ratio IC50 |
= |
85.0 |
|
Selectivity ratio of IC50 for His6-tagged recombinant full length human N-terminal PI3Kbeta to IC50 for His-tagged recombinant human PI3K p110delta/p85alpha |
CHEMBL4385593 |
| Unchecked |
Ratio IC50 |
= |
35.0 |
|
Selectivity ratio of IC50 for His-tagged recombinant human full length PI3K p110gamma to IC50 for His-tagged recombinant human PI3K p110delta/p85alpha |
CHEMBL4385593 |
| ADMET |
T1/2 |
= |
0.519 |
hr |
Half life in Sprague-Dawley rat at 2 mg/kg, iv by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
AUC |
= |
1396.0 |
ng.hr.mL-1 |
AUC (0 to t) in Sprague-Dawley rat at 2 mg/kg, iv by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
Vdss |
= |
0.884 |
L.kg-1 |
Volume of distribution at steady state in Sprague-Dawley rat at 2 mg/kg, iv by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
CL |
= |
24.5 |
mL.min-1.kg-1 |
Clearance in Sprague-Dawley rat at 2 mg/kg, iv by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
Cmax |
= |
5577.35 |
nM |
Cmax in Sprague-Dawley rat at 10 mg/kg, po by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
AUC |
= |
3191.0 |
ng.hr.mL-1 |
AUC (0 to t) in Sprague-Dawley rat at 10 mg/kg, po by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
F |
= |
45.8 |
% |
Oral bioavailability in Sprague-Dawley rat at 10 mg/kg by LC/MS/MS analysis |
CHEMBL4385593 |
| ADMET |
T1/2 |
= |
1.03 |
hr |
Half life in Sprague-Dawley rat at 10 mg/kg, po by LC/MS/MS analysis |
CHEMBL4385593 |
| TMD8 |
IC50 |
= |
795.0 |
nM |
Antiproliferative activity against human TMD8 cells |
CHEMBL4390691 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
571.0 |
nM |
Inhibition of human PI3Kbeta using PIP2 as substrate after 1 hr |
CHEMBL4390691 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
92.0 |
nM |
Inhibition of human PI3Kgamma using PIP2 as substrate after 1 hr |
CHEMBL4390691 |
| Serine/threonine-protein kinase mTOR |
IC50 |
> |
1000.0 |
nM |
Inhibition of mTOR (unknown origin) assessed as reduction in p70S6K phosphorylation |
CHEMBL4390691 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
831.0 |
nM |
Inhibition of human PI3Kalpha using PIP2 as substrate after 1 hr |
CHEMBL4390691 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.1 |
nM |
Inhibition of human PI3Kdelta using PIP2 as substrate after 1 hr |
CHEMBL4390691 |
| PI3-kinase p110-delta subunit |
Inhibition |
= |
96.0 |
% |
Inhibition of human PI3Kdelta using PIP2 as substrate at 100 nM after 1 hr relative to control |
CHEMBL4390691 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
1.2 |
nM |
Inhibition of PI3K delta (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay |
CHEMBL4396940 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
177.2 |
nM |
Inhibition of PI3K alpha (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay |
CHEMBL4396940 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
139.1 |
nM |
Inhibition of PI3K beta (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay |
CHEMBL4396940 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
145.3 |
nM |
Inhibition of PI3K gamma (unknown origin) using phosphatidyl inositol as substrate measured after 60 mins in presence of ATP by Kinase-Glo Plus reagent-based luminescence assay |
CHEMBL4396940 |
| SU-DHL-6 |
IC50 |
= |
33.0 |
nM |
Antiproliferative activity against human SUDHL6 cells by MTT assay |
CHEMBL4396940 |
| Ramos |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human Ramos cells by MTT assay |
CHEMBL4396940 |
| Raji |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human Raji cells by MTT assay |
CHEMBL4396940 |
| HCT-116 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human HCT116 cells by MTT assay |
CHEMBL4396940 |
| MCF7 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human MCF7 cells by MTT assay |
CHEMBL4396940 |
| CCRF-CEM |
GI50 |
= |
22300.0 |
nM |
Antiproliferative activity against human CCRF-CEM cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| HOP-62 |
GI50 |
> |
100000.0 |
nM |
Antiproliferative activity against human HOP62 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| HOP-92 |
GI50 |
= |
14100.0 |
nM |
Antiproliferative activity against human HOP92 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| HCC 2998 |
GI50 |
= |
38500.0 |
nM |
Antiproliferative activity against human HCC2998 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| KM12 |
GI50 |
= |
1200.0 |
nM |
Antiproliferative activity against human KM12 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| SNB-75 |
GI50 |
= |
1200.0 |
nM |
Antiproliferative activity against human SNB75 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| U-251 |
GI50 |
= |
53200.0 |
nM |
Antiproliferative activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| LOX IMVI |
GI50 |
= |
33500.0 |
nM |
Antiproliferative activity against human LOXIMVI cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| M14 |
GI50 |
= |
37800.0 |
nM |
Antiproliferative activity against human M14 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| IGROV-1 |
GI50 |
= |
4800.0 |
nM |
Antiproliferative activity against human IGROV1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| OVCAR-3 |
GI50 |
= |
17700.0 |
nM |
Antiproliferative activity against human OVCAR3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| A498 |
GI50 |
= |
1100.0 |
nM |
Antiproliferative activity against human A498 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| CAKI-1 |
GI50 |
= |
20500.0 |
nM |
Antiproliferative activity against human Caki1 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| RXF 393 |
GI50 |
= |
1400.0 |
nM |
Antiproliferative activity against human RXF393 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| MDA-MB-231 |
GI50 |
= |
42300.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| Hs-578T |
GI50 |
= |
6000.0 |
nM |
Antiproliferative activity against human Hs578T cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| T47D |
GI50 |
= |
5200.0 |
nM |
Antiproliferative activity against human T47D cells assessed as cell growth inhibition measured after 48 hrs by SRB assay |
CHEMBL4402587 |
| MV4-11 |
Inhibition |
|
|
% |
Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability at 2.5 to 5 uM after 72 hrs by tryphan blue assay |
CHEMBL4402587 |
| PI3-kinase p110-delta subunit |
Activity |
|
|
|
Binding affinity to PI3Kdelta in human MV4-11 cells assessed as increase in cellular protein stabilization at 1 uL preincubated for 1 hr followed by heating at 52 degree C for 3.5 mins by CETSA |
CHEMBL4402587 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
10.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay |
CHEMBL4414631 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
10000.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay |
CHEMBL4414631 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
1995.26 |
nM |
Inhibition of PI3Kbeta (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay |
CHEMBL4414631 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
199.53 |
nM |
Inhibition of PI3Kgamma (unknown origin) using biotin-PIP3 as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence polarization assay |
CHEMBL4414631 |
| Neutrophils |
IC50 |
= |
70.0 |
nM |
Anti-inflammatory activity in FMLP/CB-stimulated human neutrophils assessed as inhibition of superoxide generation preincubated for 5 mins followed by cytochalasin B and FMLP stimulation for 3 mins and 10 mins respectively by ferricytochrome c reduction based assay |
CHEMBL4428034 |
| Neutrophils |
Inhibition |
= |
103.0 |
% |
Anti-inflammatory activity in FMLP/CB-stimulated human neutrophils assessed as inhibition of superoxide generation at 10 uM preincubated for 5 mins followed by cytochalasin B and FMLP stimulation for 3 mins and 10 mins respectively by ferricytochrome c reduction based assay relative to control |
CHEMBL4428034 |
| Neutrophils |
Inhibition |
= |
100.0 |
% |
Anti-inflammatory activity in FMLP/CB-stimulated human neutrophils assessed as inhibition of elastase release at 10 uM preincubated for 5 mins followed by FMLP/CB stimulation for 10 mins using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate relative to control |
CHEMBL4428034 |
| Neutrophils |
IC50 |
= |
300.0 |
nM |
Anti-inflammatory activity in FMLP/CB-stimulated human neutrophils assessed as inhibition of elastase release preincubated for 5 mins followed by FMLP/CB stimulation for 10 mins using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate |
CHEMBL4428034 |
| Replicase polyprotein 1ab |
Inhibition |
= |
30.29 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| Replicase polyprotein 1ab |
Inhibition |
= |
9.69 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| Replicase polyprotein 1ab |
Inhibition |
= |
-0.9913 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.1 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
0.18 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.23 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
0.18 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.1 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.23 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
20000.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
19952.62 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
3.4 |
nM |
Inhibition of human full-length recombinant His-tagged PI3K p110delta/p85alpha expressed in baculovirus expression system using PIP2 as substrate measured after 2 hrs by ADP-Glo luminescence assay |
CHEMBL4680196 |
| SU-DHL-6 |
GI50 |
= |
34.0 |
nM |
Antiproliferative activity against human SU-DHL-6 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay |
CHEMBL4680196 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
6.0 |
nM |
Inhibition of human PI3Kdelta using substrate PIP2:PS and ATP incubated for 1 hr by ADP-Glo assay |
CHEMBL4699641 |
| Unchecked |
Ratio IC50 |
= |
65.0 |
|
Selectivity index, ratio of IC50 for human PI3Kalpha to IC50 for human PI3Kdelta |
CHEMBL4699641 |
| Unchecked |
Ratio IC50 |
= |
141.0 |
|
Selectivity index, ratio of IC50 for human PI3Kbeta to IC50 for human PI3Kdelta |
CHEMBL4699641 |
| Unchecked |
Ratio IC50 |
= |
11.0 |
|
Selectivity index, ratio of IC50 for human PI3Kgamma to IC50 for human PI3Kdelta |
CHEMBL4699641 |
| ADMET |
AUC |
= |
3086.64 |
ng.hr.mL-1 |
AUClast in BALB/C mouse at 10 mg/kg, iv measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
0.43 |
hr |
Terminal Half life in BALB/C mouse at 10 mg/kg, iv measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
CL |
= |
54.0 |
mL.min-1.kg-1 |
Clearance in BALB/C mouse at 10 mg/kg, iv measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
Tmax |
= |
0.25 |
hr |
Tmax in BALB/C mouse at 30 mg/kg, po measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
Cmax |
= |
6980.0 |
nM |
Cmax in BALB/C mouse at 30 mg/kg,po measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
AUC |
= |
3842.73 |
ng.hr.mL-1 |
AUClast in BALB/C mouse at 30 mg/kg, po measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
0.83 |
hr |
Half life in BALB/C mouse at 30 mg/kg, po measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| ADMET |
F |
= |
37.6 |
% |
Oral bioavailability in BALB/C mouse at 30 mg/kg measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| SU-DHL-6 |
IC50 |
= |
22.5 |
nM |
Anticancer activity against human SUDHL-6 assessed as inhibition of ATP level measured after 96 hrs by CellTiter-Glo reagent assay |
CHEMBL4715876 |
| OCI-Ly10 |
IC50 |
= |
31.9 |
nM |
Anticancer activity against human OCILY10 assessed as inhibition of ATP level measured after 96 hrs by CellTiter-Glo reagent assay |
CHEMBL4715876 |
| TMD8 |
IC50 |
= |
7.3 |
nM |
Anticancer activity against human TMD8 assessed as inhibition of ATP level measured after 96 hrs by CellTiter-Glo reagent assay |
CHEMBL4715876 |
| OCI-Ly10 |
Activity |
= |
828.42 |
mm3 |
Antitumor activity against human OCI-LY10 cells xenografted in CB.17 SCID mouse assessed as tumor volume at 3 mg/kg, po once daily for 24 days (Rvb = 1430.74 +/- 363.89 mm3) |
CHEMBL4715876 |
| OCI-Ly10 |
TGI |
= |
47.33 |
% |
Antitumor activity against human OCI-LY10 cells xenografted in CB.17 SCID mouse assessed as tumor growth inhibition at 3 mg/kg, po once daily for 24 days relative to control |
CHEMBL4715876 |
| OCI-Ly10 |
Activity |
= |
0.48 |
g |
Antitumor activity against human OCI-LY10 cells xenografted in CB.17 SCID mouse assessed as tumor weight at 3 mg/kg, po once daily for 24 days (Rvb = 0.86 +/- 0.26 g) |
CHEMBL4715876 |
| ADMET |
Activity |
= |
20.68 |
g |
Toxicity in CB.17 SCID mouse xenografted with OCI-LY10 cells assessed as effect on body weight at 3 mg/kg, po once daily for 24 days (Rvb = 22.6 +/- 0.34 g) |
CHEMBL4715876 |
| ADMET |
Drug uptake |
= |
0.15 |
uM |
Drug uptake in CB.17 SCID mouse tumor xenografted with OCI-LY10 cells at 3 mg/kg, po once daily for 24 days |
CHEMBL4715876 |
| ADMET |
Cp |
= |
0.04 |
uM |
Plasma concentration in CB.17 SCID mouse xenografted with OCI-LY10 cells at 3 mg/kg, po once daily for 24 days |
CHEMBL4715876 |
| TMD8 |
Activity |
= |
1312.58 |
mm3 |
Antitumor activity against human TMD-8 cells xenografted in CB.17 SCID mouse assessed as tumor volume at 3 mg/kg, po once daily for 19 days (Rvb = 1811.14 +/- 301.55 mm3) |
CHEMBL4715876 |
| TMD8 |
TGI |
= |
29.28 |
% |
Antitumor activity against human TMD-8 cells xenografted in CB.17 SCID mouse assessed as tumor growth inhibition at 3 mg/kg, po once daily for 19 days relative to control |
CHEMBL4715876 |
| TMD8 |
Activity |
= |
1.07 |
g |
Antitumor activity against human TMD-8 cells xenografted in CB.17 SCID mouse xenografted with OCI-LY10 cells assessed as tumor weight at 3 mg/kg, po once daily for 19 days (Rvb = 1.3 +/- 0.3 g) |
CHEMBL4715876 |
| ADMET |
Activity |
= |
25.03 |
g |
Toxicity in CB.17 SCID mouse xenografted with TMD-8 cells assessed as effect on body weight at 3 mg/kg, po once daily for 19 days (Rvb = 28.66 +/- 0.83 g) |
CHEMBL4715876 |
| ADMET |
Drug uptake |
= |
0.14 |
uM |
Drug uptake in CB.17 SCID mouse tumor xenografted with TMD-8 cells at 3 mg/kg, po once daily for 19 days |
CHEMBL4715876 |
| ADMET |
Cp |
= |
0.02 |
uM |
Plasma concentration in CB.17 SCID mouse xenografted with TMD-8 cells at 3 mg/kg, po once daily for 19 days |
CHEMBL4715876 |
| SU-DHL-6 |
Activity |
= |
1276.78 |
mm3 |
Antitumor activity against human SUDHL-6 cells xenografted in CB.17 SCID mouse assessed as tumor volume at 5 mg/kg, po once daily for 15 days (Rvb = 1982 +/- 289.04 mm3) |
CHEMBL4715876 |
| SU-DHL-6 |
TGI |
= |
38.52 |
% |
Antitumor activity against human SUDHL-6 cells xenografted in CB.17 SCID mouse assessed as tumor growth inhibition at 5 mg/kg, po once daily for 15 days relative to control |
CHEMBL4715876 |
| SU-DHL-6 |
Activity |
= |
1.25 |
g |
Antitumor activity against human SUDHL-6 cells xenografted in CB.17 SCID mouse assessed as tumor weight at 5 mg/kg, po once daily for 15 days (Rvb = 1.69 +/- 0.32 g) |
CHEMBL4715876 |
| ADMET |
Activity |
= |
23.84 |
g |
Toxicity in CB.17 SCID mouse xenografted with SUDHL-6 cells assessed as effect on body weight at 5 mg/kg, po once daily for 15 days (Rvb = 28.13 +/- 0.65 g) |
CHEMBL4715876 |
| ADMET |
Drug uptake |
= |
0.08 |
uM |
Drug uptake in CB.17 SCID mouse tumor xenografted with SUDHL-6 cells assessed as effect on body weight at 5 mg/kg, po once daily for 15 days |
CHEMBL4715876 |
| ADMET |
Cp |
= |
0.03 |
uM |
Plasma concentration in CB.17 SCID mouse tumor xenografted with SUDHL-6 cells assessed as effect on body weight at 5 mg/kg, po once daily for 15 days |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
2.31 |
hr |
Half life in Beagle dog at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
CL |
= |
0.76 |
mL.min-1.kg-1 |
Clearance in Beagle dog at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Tmax |
= |
0.08 |
hr |
Tmax in Sprague-Dawley rat at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Cmax |
= |
3460.0 |
nM |
Cmax in Sprague-Dawley rat at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
1.89 |
hr |
Half life in Sprague-Dawley rat at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
CL |
= |
47.8 |
mL.min-1.kg-1 |
Clearance in Sprague-Dawley rat at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Vdss |
= |
2.49 |
L.kg-1 |
Volume of distribution at steady state in Sprague-Dawley rat at 3 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Tmax |
= |
3.0 |
hr |
Tmax in Sprague-Dawley rat at 3 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Cmax |
= |
310.0 |
nM |
Cmax in Sprague-Dawley rat at 3 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
1.52 |
hr |
Half life in Sprague-Dawley rat at 3 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
F |
= |
39.0 |
% |
Oral bioavailability in Sprague-Dawley rat at 3 mg/kg measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Tmax |
= |
0.08 |
hr |
Tmax in Beagle dog at 1 mg/kg, iv measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Tmax |
= |
1.0 |
hr |
Tmax in Beagle dog at 1 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Cmax |
= |
500.0 |
nM |
Cmax in Beagle dog at 1 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
T1/2 |
= |
1.99 |
hr |
Half life in Beagle dog at 1 mg/kg, po measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
F |
= |
48.0 |
% |
Oral bioavailability in Beagle dog at 1 mg/kg measured upto 24 hrs by LC-MS/MS analysis |
CHEMBL4715876 |
| ADMET |
Vdss |
= |
0.73 |
L.kg-1 |
Volume of distribution at steady state in BALB/C mouse at 10 mg/kg, iv measured upto 24 hrs by LC-MS analysis |
CHEMBL4715876 |
| HEK-293T |
Cell Viability |
= |
34.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
8.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
13.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
2.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with HEK293T |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| U2OS |
Cell Viability |
= |
0.0 |
|
Incucyte cell viability with U2OS |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Cell Viability |
= |
1.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL4689842 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
4.7 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL4725342 |
| Unchecked |
Ratio IC50 |
> |
106.0 |
|
Selectivity index, ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4725342 |
| PI3-kinase p110-alpha subunit |
IC50 |
> |
500.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) |
CHEMBL4725342 |
| PI3-kinase p110-beta subunit |
IC50 |
> |
500.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) |
CHEMBL4725342 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
245.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) |
CHEMBL4725342 |
| OCI-Ly3 |
IC50 |
= |
5200.0 |
nM |
Antiproliferative activity against human OCILY3 assessed as reduction in cell growth by MTS assay |
CHEMBL4725342 |
| OCI-Ly10 |
IC50 |
> |
10000.0 |
nM |
Antiproliferative activity against human OCILY10 assessed as reduction in cell growth by MTS assay |
CHEMBL4725342 |
| SU-DHL-6 |
IC50 |
= |
120.0 |
nM |
Antiproliferative activity against human SU-DHL-6 assessed as reduction in cell growth by MTS assay |
CHEMBL4725342 |
| JeKo-1 |
IC50 |
= |
120.0 |
nM |
Antiproliferative activity against human JeKo-1 assessed as reduction in cell growth by MTS assay |
CHEMBL4725342 |
| Vero |
IC50 |
> |
20000.0 |
nM |
Cytotoxicity against monkey Vero cells assessed as reduction in cell viability by MTS assay |
CHEMBL4725342 |
| L02 |
IC50 |
> |
20000.0 |
nM |
Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTS assay |
CHEMBL4725342 |
| HEK293 |
IC50 |
> |
20000.0 |
nM |
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability by MTS assay |
CHEMBL4725342 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of recombinant human His-tagged PI3Kdelta expressed in baculovirus expression system using PIP2:PS as substrate incubated for 1 hr by invitrogen adapta assay |
CHEMBL4725342 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of recombinant human His-tagged PI3Kalpha expressed in insect cell expression system using PIP2:PS as substrate incubated for 1 hr by invitrogen adapta assay |
CHEMBL4725342 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
565.0 |
nM |
Inhibition of recombinant human His-tagged PI3Kbeta expressed in insect cell expression system using PIP2:PS as substrate incubated for 1 hr by invitrogen adapta assay |
CHEMBL4725342 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of recombinant human His-tagged PI3Kgamma expressed in baculovirus expression system using PIP2:PS as substrate incubated for 1 hr by invitrogen adapta assay |
CHEMBL4725342 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL4806966 |
| Unchecked |
Ratio IC50 |
= |
2.5 |
|
Selectivity index, ratio of IC50 for human PIK3C2B to IC50 for PI3Kdelta (unknown origin) |
CHEMBL4806966 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of recombinant full-length human His-tagged PI3Kalpha expressed in insect cells by Selectscreen kinase assay |
CHEMBL4831512 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
564.0 |
nM |
Inhibition of recombinant full-length human His-tagged PI3Kbeta expressed in insect cells by Selectscreen kinase assay |
CHEMBL4831512 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of recombinant full-length human His-tagged PI3Kgamma expressed in baculovirus expression system by Selectscreen kinase assay |
CHEMBL4831512 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of PI3Kdelta (unknown origin) by Selectscreen kinase assay |
CHEMBL4831512 |
| SU-DHL-5 |
Activity |
= |
41.34 |
% |
Antiproliferative activity against human SU-DHL-5 cells assessed as cell viability at 10 uM by CellTiter-Glo luminescent cell viability assay (Rvb = 100%) |
CHEMBL4834477 |
| MOLT-4 |
Activity |
= |
74.57 |
% |
Antiproliferative activity against human MOLT-4 cells assessed as cell viability at 20 uM by CellTiter-Glo luminescent cell viability assay (Rvb = 100%) |
CHEMBL4834477 |
| PI3-kinase p110-alpha/p85-alpha |
IC50 |
= |
409.0 |
nM |
Inhibition of recombinant human full length N-terminal His-tagged p110alpha/p85alpha expressed in baculovirus expression system measured after 60 mins in presence of ATP by ATP-competitive binding assay |
CHEMBL4834477 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
613.0 |
nM |
Inhibition of recombinant human full length His-tagged p110beta expressed in baculovirus expression system measured after 60 mins in presence of ATP by ATP-competitive binding assay |
CHEMBL4834477 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
27.4 |
nM |
Inhibition of recombinant human full length His-tagged p110gamma expressed in baculovirus expression system measured after 60 mins in presence of ATP by ATP-competitive binding assay |
CHEMBL4834477 |
| PI3-kinase p110-delta/p85-alpha |
IC50 |
= |
1.08 |
nM |
Inhibition of recombinant human full length His-tagged p110delta/p85alpha expressed in baculovirus expression system measured after 60 mins in presence of ATP by ATP-competitive binding assay |
CHEMBL4834477 |
| Unchecked |
Ratio IC50 |
= |
25.37 |
|
Selectivity ratio of IC50 for recombinant human full length His-tagged p110gamma expressed in baculovirus expression system to IC50 for recombinant human full length His-tagged p110delta/p85alpha expressed in baculovirus expression system |
CHEMBL4834477 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of PI3Kdelta in human SU-DHL-5 cells assessed as inhibition of AKT phosphorylation at Ser473 residue at 1 to 5 uM measured after 3 hrs by western blot assay |
CHEMBL4834477 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of PI3Kdelta in human MOLT-4 cells assessed as inhibition of AKT phosphorylation at Ser473 residue at 1 to 5 uM measured after 3 hrs by western blot assay |
CHEMBL4834477 |
| SU-DHL10 |
Activity |
= |
12.2 |
% |
Induction of apoptosis in human SU-DHL-10 cells assessed as viable cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 90%) |
CHEMBL4834477 |
| SU-DHL10 |
Activity |
= |
55.7 |
% |
Induction of apoptosis in human SU-DHL-10 cells assessed as early apoptotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 6.32%) |
CHEMBL4834477 |
| SU-DHL10 |
Activity |
= |
30.4 |
% |
Induction of apoptosis in human SU-DHL-10 cells assessed as late apoptotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 3.48%) |
CHEMBL4834477 |
| SU-DHL10 |
Activity |
= |
1.7 |
% |
Induction of apoptosis in human SU-DHL-10 cells assessed as necrotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 0.2%) |
CHEMBL4834477 |
| MOLT-4 |
Activity |
= |
56.5 |
% |
Induction of apoptosis in human MOLT-4 cells assessed as viable cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 95.3%) |
CHEMBL4834477 |
| MOLT-4 |
Activity |
= |
19.2 |
% |
Induction of apoptosis in human MOLT-4 cells assessed as early apoptotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 2.04%) |
CHEMBL4834477 |
| MOLT-4 |
Activity |
= |
22.0 |
% |
Induction of apoptosis in human MOLT-4 cells assessed as late apoptotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 2.17%) |
CHEMBL4834477 |
| MOLT-4 |
Activity |
= |
2.34 |
% |
Induction of apoptosis in human MOLT-4 cells assessed as necrotic cells at 20 uM measured after 24 hrs by AnnexinV-FITC/PI staining based flowcytometry method (Rvb = 0.51%) |
CHEMBL4834477 |
| MOLT-4 |
Inhibition |
|
|
% |
Antitumour activity against human MOLT-4 cells xenografted in Balb/c nude mouse assessed as inhibition of tumour growth at 10 mg/kg, po administered via gavage qd for 57 days |
CHEMBL4834477 |
| ADMET |
Activity |
|
|
|
Toxicity in Balb/c nude mouse xenografted with human MOLT-4 cells assessed as changes in body weight at 10 mg/kg, po administered via gavage qd for 57 days |
CHEMBL4834477 |
| ADMET |
AUC |
= |
201.88 |
ng.hr.mL-1 |
AUC (last) in Sprague-Dawley rat at 3 mg/kg, po measured for 24 hrs by LC-MS/MS analysis |
CHEMBL4834477 |
| ADMET |
Cmax |
= |
127.63 |
nM |
Cmax in Sprague-Dawley rat at 3 mg/kg, po measured for 24 hrs by LC-MS/MS analysis |
CHEMBL4834477 |
| ADMET |
Tmax |
= |
0.5 |
hr |
Tmax in Sprague-Dawley rat at 3 mg/kg, po measured for 24 hrs by LC-MS/MS analysis |
CHEMBL4834477 |
| ADMET |
T1/2 |
= |
2.7 |
hr |
Half life in Sprague-Dawley rat at 3 mg/kg, po measured for 24 hrs by LC-MS/MS analysis |
CHEMBL4834477 |
| MRC5 |
Inhibition |
= |
18.41 |
% |
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability at 20 uM measured after 48 hrs by MTT assay |
CHEMBL4834477 |
| MRC5 |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MRC5 cells assessed as inhibition of cell viability measured after 48 hrs by MTT assay |
CHEMBL4834477 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of PI3Kdelta in human SU-DHL-5 cells assessed as inhibition of AKT phosphorylation at Thr308 residue at 1 to 5 uM measured after 3 hrs by western blot assay |
CHEMBL4834477 |
| PI3-kinase p110-delta subunit |
Inhibition |
|
|
% |
Inhibition of PI3Kdelta in human MOLT-4 cells assessed as inhibition of AKT phosphorylation at Thr308 residue at 1 to 5 uM measured after 3 hrs by western blot assay |
CHEMBL4834477 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) using PIP2 as substrate in presence of ATP measured after 60 mins by ADP-Glo assay |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
3.44 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at subG1 phase at 1 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =4.02 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
47.9 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G1 phase at 1 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =46.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
31.7 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at S phase at 1 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =31.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
13.9 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G2 phase at 1 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =14.7 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
5.71 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at subG1 phase at 2 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =4.02 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
48.4 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G1 phase at 2 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =46.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
32.9 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at S phase at 2 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =31.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
12.4 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G2 phase at 2 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =14.7 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
2.6 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at subG1 phase at 5 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =4.02 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
49.6 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G1 phase at 5 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =46.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
32.8 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at S phase at 5 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =31.8 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
13.6 |
% |
Induction of cell cycle arrest in human MOLM16 cells assessed as accumulation at G2 phase at 5 uM incubated for 24 hrs by propidium iodide /RNase staining based flow cytometry(Rvb =14.7 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
77.0 |
% |
Induction of apoptosis in human MOLM16 cells assessed as viable cells at 1 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 76.3 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
13.9 |
% |
Induction of apoptosis in human MOLM16 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 16.4 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
7.95 |
% |
Induction of apoptosis in human MOLM16 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 6.77 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
1.14 |
% |
Induction of apoptosis in human MOLM16 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 0.44 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
73.2 |
% |
Induction of apoptosis in human MOLM16 cells assessed as viable cells at 2 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 76.3 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
18.2 |
% |
Induction of apoptosis in human MOLM16 cells assessed as early apoptotic cells at 2 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 16.4 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
10.1 |
% |
Induction of apoptosis in human MOLM16 cells assessed as late apoptotic cells at 2 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 6.77 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
0.5 |
% |
Induction of apoptosis in human MOLM16 cells assessed as necrotic cells at 2 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 0.44 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
74.6 |
% |
Induction of apoptosis in human MOLM16 cells assessed as viable cells at 5 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 76.3 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
14.8 |
% |
Induction of apoptosis in human MOLM16 cells assessed as early apoptotic cells at 5 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 16.4 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
9.19 |
% |
Induction of apoptosis in human MOLM16 cells assessed as late apoptotic cells at 5 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 6.77 %) |
CHEMBL4840313 |
| Unchecked |
Activity |
= |
1.49 |
% |
Induction of apoptosis in human MOLM16 cells assessed as necrotic cells at 5 uM incubated for 48 hrs by Annexin V and propidium iodide Staining based assay (Rvb = 0.44 %) |
CHEMBL4840313 |
| Fibroblasts |
Total Cell Count |
= |
77.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
231110.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
22.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
77.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
70.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
100.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
6.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
73.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
58.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
58.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
84.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
67.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
43.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
21.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
99.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
588.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
81.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
22.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
46.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
34.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
29.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
691.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
69.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
110.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
43.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
56.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
66.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
22.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
28.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
35.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
99.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
911.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
81.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
43.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
20.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
35.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
865.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
888.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
20.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
80.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
44.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
24.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
87.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
865.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
49.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
184.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
19.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
90.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
85.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
36.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
211.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
53.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
60.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
44.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
231110.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
35.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
40.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
56.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
60.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
33.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
55.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
63.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
58.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
47.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
69.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
56.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
50.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
53.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
6.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
84.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
52.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
31.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
2065.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
83.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
22.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
68.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
28.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
3025.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
16.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
73.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
1315.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
89.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
64.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
1765.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
134.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
156.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
59.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
180.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
63.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
90.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
18.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
199.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
36.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
244.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
62.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
33.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
66.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
94.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
19.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
276.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
37.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
162.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
63.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
26.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
46.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
53.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
34.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
47.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
199.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
36.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
132.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
75.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
90.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
14.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
84.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
85.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
45.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
139.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
148.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
28.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
94.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
42.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
57.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
32.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
178.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
210.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
62.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
45.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
85.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
54.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
17.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
28.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
276.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
37.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
613.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
84.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
67.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
82.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
48.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
16.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
838.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
79.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
199.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
58.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
41.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
230.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
69.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
222.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
14.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
11.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
88.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
91.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
56.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
8.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
20.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
230.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
69.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
95.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
18.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
11.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
20.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
99.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
87.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
587.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
13.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
84.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
94.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
11.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
81.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
838.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
79.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
146.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
68.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
28.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
29.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
82.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
60.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
21.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
30.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
178.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
31.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
221.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
86.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
73.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
22.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
26.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
242.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
61.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
146.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
12.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
93.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
30.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
85.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
70.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
25.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
13.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
6.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
156.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
59.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
2772.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
83.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
45.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
22.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
68.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
29.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
96.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
3025.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
16.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
73.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
500.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
81.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
60.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
23.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
81.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
3.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
691.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
18.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
69.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
103.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
3.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
18.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
20.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
79.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
84.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
14.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
18.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
99.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
87.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Total Cell Count |
= |
130.0 |
|
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Fragmented Nuclei % |
= |
7.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitotic Cells (%) |
= |
75.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
27.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
9.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Hoechst High Intensity Objects (%) |
= |
16.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Normal (%) |
= |
83.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Apoptotic (%) |
= |
0.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Pyknosed Nuclei (%) |
= |
2.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitotic Cells (%) |
= |
100.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Tubulin-Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Mitochondria Different-Phenotype (%) |
= |
28.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Population Membrane Permeable-Phenotype (%) |
= |
4.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Total Cells |
= |
139.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Apoptotic Cells (%) |
= |
24.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| U2OS |
Control DMSO Healthy Nuclei (%) |
= |
88.0 |
% |
Multiplex assay against U2OS |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
1603.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
9.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
91.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
7.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
10.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
1.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
1765.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
8.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
86.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
211.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
25.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
13.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
34.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
1.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
12.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
87.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
59.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
54.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
40.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
5.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
242.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
65.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
61.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
1058.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
32.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
15.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
78.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
84.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
28.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
1080.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Total Cell Count |
= |
995.0 |
|
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Fragmented Nuclei % |
= |
5.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Pyknosed Nuclei (%) |
= |
16.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitotic Cells (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
32.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Hoechst High Intensity Objects (%) |
= |
2.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Normal (%) |
= |
97.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Apoptotic (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Fragmented Nuclei (%) |
= |
4.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitotic Cells (%) |
= |
85.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Tubulin-Different-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Mitochondria Different-Phenotype (%) |
= |
22.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Total Cells |
= |
1080.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Apoptotic Cells (%) |
= |
14.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| HEK-293T |
Control DMSO Healthy Nuclei (%) |
= |
77.0 |
% |
Multiplex assay against HEK293T |
CHEMBL4689842 |
| Fibroblasts |
Total Cell Count |
= |
156.0 |
|
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Fragmented Nuclei % |
= |
27.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Pyknosed Nuclei (%) |
= |
18.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitotic Cells (%) |
= |
19.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Tubulin Phenotype Different Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Mitochondria Different-Phenotype Cells (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Membrane Permeable-Phenotype Cells (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Growth Rate |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Hoechst High Intensity Objects (%) |
= |
10.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Normal (%) |
= |
89.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Apoptotic (%) |
= |
95.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Healthy Nuclei (%) |
= |
51.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Fragmented Nuclei (%) |
= |
30.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Pyknosed Nuclei (%) |
= |
17.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitotic Cells (%) |
= |
4.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Tubulin-Different-Phenotype (%) |
= |
2.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Mitochondria Different-Phenotype (%) |
= |
15.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Population Membrane Permeable-Phenotype (%) |
= |
0.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Total Cells |
= |
211.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Apoptotic Cells (%) |
= |
80.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| Fibroblasts |
Control DMSO Healthy Nuclei (%) |
= |
53.0 |
% |
Multiplex assay against human fibroblast |
CHEMBL4689842 |
| HEK-293T |
Cell Viability |
= |
19.21 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
6.94 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.06 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
-0.03 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
4.85 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
3.0 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.2 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.76 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.46 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.59 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
-0.73 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
0.36 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.52 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.57 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.4 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.55 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
-0.05 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
0.48 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.56 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.7 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.44 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.68 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
-0.04 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
0.59 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.64 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| HEK-293T |
Cell Viability |
= |
0.68 |
|
Incucyte cell viability with HEK293T |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.59 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| U2OS |
Cell Viability |
= |
0.73 |
|
Incucyte cell viability with U2OS |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
-0.13 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Fibroblasts |
Cell Viability |
= |
0.75 |
|
Incucyte cell viability with human fibroblast |
CHEMBL5058564 |
| Tyrosine-protein kinase ABL |
Delta TM |
= |
-0.1913 |
C |
Thermal Shift Assay. Domain: start/stop: S229-K512 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Aurora-A |
Delta TM |
= |
0.281 |
C |
Thermal Shift Assay. Domain: start/stop: E122-S403 |
CHEMBL4632348 |
| Bromodomain-containing protein 4 |
Delta TM |
= |
0.03447 |
C |
Thermal Shift Assay. Domain: start/stop: N44-E168 |
CHEMBL4632348 |
| Peregrin |
Delta TM |
= |
0.4331 |
C |
Thermal Shift Assay. Domain: start/stop: M626-G746 |
CHEMBL4632348 |
| Cyclin-dependent kinase 2 |
Delta TM |
= |
-0.6419 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L298 |
CHEMBL4632348 |
| Casein kinase I delta |
Delta TM |
= |
-0.1565 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 3 |
Delta TM |
= |
0.05233 |
C |
Thermal Shift Assay. Domain: start/stop: P449-E759 |
CHEMBL4632348 |
| Glycogen synthase kinase-3 beta |
Delta TM |
= |
-0.008089 |
C |
Thermal Shift Assay. Domain: start/stop: M26-R383 |
CHEMBL4632348 |
| MAP kinase ERK2 |
Delta TM |
= |
-0.04486 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S360 |
CHEMBL4632348 |
| Transcription intermediary factor 1-alpha |
Delta TM |
= |
-0.2391 |
C |
Thermal Shift Assay. Domain: start/stop: G861-E979 |
CHEMBL4632348 |
| Tyrosine-protein kinase ABL |
Delta TM |
= |
0.82 |
C |
Thermal Shift Assay. Domain: start/stop: S229-K512 |
CHEMBL4632348 |
| Serine/threonine-protein kinase Aurora-A |
Delta TM |
= |
-0.27 |
C |
Thermal Shift Assay. Domain: start/stop: E122-S403 |
CHEMBL4632348 |
| Bromodomain-containing protein 4 |
Delta TM |
= |
-1.67 |
C |
Thermal Shift Assay. Domain: start/stop: N44-E168 |
CHEMBL4632348 |
| Peregrin |
Delta TM |
= |
-1.86 |
C |
Thermal Shift Assay. Domain: start/stop: M626-G740 |
CHEMBL4632348 |
| Cyclin-dependent kinase 2 |
Delta TM |
= |
0.39 |
C |
Thermal Shift Assay. Domain: start/stop: M1-L298 |
CHEMBL4632348 |
| Casein kinase I delta |
Delta TM |
= |
0.0 |
C |
Thermal Shift Assay. Domain: start/stop: M1-K294 |
CHEMBL4632348 |
| Fibroblast growth factor receptor 3 |
Delta TM |
= |
0.03 |
C |
Thermal Shift Assay. Domain: start/stop: P449-E759 |
CHEMBL4632348 |
| Glycogen synthase kinase-3 beta |
Delta TM |
= |
-0.32 |
C |
Thermal Shift Assay. Domain: start/stop: M26-R383 |
CHEMBL4632348 |
| MAP kinase ERK2 |
Delta TM |
= |
-0.09 |
C |
Thermal Shift Assay. Domain: start/stop: M1-S360 |
CHEMBL4632348 |
| Transcription intermediary factor 1-alpha |
Delta TM |
= |
-0.98 |
C |
Thermal Shift Assay. Domain: start/stop: G861-E979 |
CHEMBL4632348 |
| DOHH-2 |
IC50 |
= |
860.0 |
nM |
Cytotoxicity against human DOHH-2 cells expressing BTK and PI3kdelta assessed as inhibition of cell growth incubated for 72 hrs by celltiter-glo assay |
CHEMBL5126539 |
| DOHH-2 |
Activity |
= |
38.1 |
% |
Antitumor activity against human DOHH-2 cells xenografted in CB17/SCID mouse assessed as reduction in tumor growth at 25 mg/kg, po administered twice daily in combination with ibrutinib at 15 mg/kg for 30 days and measured twice a week relative to control |
CHEMBL5126539 |
| DOHH-2 |
Activity |
= |
57.9 |
% |
Antitumor activity against human DOHH-2 cells xenografted in CB17/SCID mouse assessed as reduction in tumor growth at 50 mg/kg, po administered twice daily in combination with ibrutinib at 30 mg/kg for 30 days and measured twice a week relative to control |
CHEMBL5126539 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
2.5 |
nM |
Inhibition of p110delta (unknown origin) |
CHEMBL5149968 |
| PI3-kinase p110-delta subunit |
EC50 |
= |
8.0 |
nM |
Inhibition of p110delta (unknown origin) |
CHEMBL5149968 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
31.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) |
CHEMBL5149992 |
| PI3-kinase p110-gamma subunit |
IC50 |
|
|
|
Inhibition of PI3Kgamma (unknown origin) |
CHEMBL5149992 |
| PI3-kinase p110-alpha subunit |
IC50 |
|
|
|
Inhibition of PI3Kalpha (unknown origin) |
CHEMBL5149992 |
| PI3-kinase p110-beta subunit |
IC50 |
|
|
|
Inhibition of PI3Kbeta (unknown origin) |
CHEMBL5149992 |
| ADMET |
T1/2 |
= |
6.079 |
hr |
Metabolic stability in human liver microsome assessed as half life at 10 uM in presence of NADPH incubated up to 60 hrs |
CHEMBL5149992 |
| ADMET |
CL |
= |
3.8 |
mL.min-1.g-1 |
Metabolic stability in human liver microsome assessed as intrinsic clearance at 10 uM in presence of NADPH incubated up to 60 hrs |
CHEMBL5149992 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
8695.5 |
nM |
Inhibition of PI3Kalpha in human SK-OV-3 cells assessed as reduction in AKT phosphorylation at S473 residue incubated for 30 mins |
CHEMBL5149992 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
2473.5 |
nM |
Inhibition of PI3Kbeta in human 786-0 cells assessed as reduction in AKT phosphorylation at S473 residue incubated for 30 mins |
CHEMBL5149992 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform |
IC50 |
= |
1302.0 |
nM |
Inhibition of PI3Kgamma in c5a-stimulated mouse RAW264.7 cells assessed as reduction in AKT phosphorylation at S473 residue incubated for 30 mins |
CHEMBL5149992 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
48.93 |
nM |
Inhibition of PI3Kdelta in anti-IgM-stimulated human Raji cells assessed as reduction in AKT phosphorylation at S473 residue incubated for 30 mins |
CHEMBL5149992 |
| PI3-kinase p110-delta subunit |
IC50 |
|
|
|
Inhibition of PI3Kdelta in anti-FceRI-stimulated human Basophil cells degranulation incubated for 30 mins |
CHEMBL5149992 |
| PI3-kinase p110-delta subunit |
IC50 |
|
|
|
Inhibition of PI3Kdelta in anti-IgM-stimulated human whole blood B cell degranulation incubated for 60 mins by flow cytometry |
CHEMBL5149992 |
| PI3-kinase p110-delta subunit |
IC50 |
|
|
|
Inhibition of PI3Kdelta in conA-stimulated primary human T cell proliferation incubated for 1 hr by CellTiter-glo luminescent assay |
CHEMBL5149992 |
| Mus musculus |
Activity |
|
|
|
Antiarthritic activity in collagen-induced rheumatoid arthritis DBA1/J mouse model assessed as reduction in disease severity at 20 mg/kg, po qd measured once daily for 24 to 27 days |
CHEMBL5149992 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
820.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) using PIP2 as substrate incubated for 1 hr in presence of ATP by ADP-Glo assay |
CHEMBL5154755 |
| PI3-kinase p110-beta subunit |
IC50 |
= |
565.0 |
nM |
Inhibition of PI3Kbeta (unknown origin) using PIP2 as substrate incubated for 1 hr in presence of ATP by ADP-Glo assay |
CHEMBL5154755 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
89.0 |
nM |
Inhibition of PI3Kgamma (unknown origin) using PIP2 as substrate incubated for 1 hr in presence of ATP by ADP-Glo assay |
CHEMBL5154755 |
| Bel-7402 |
Inhibition |
= |
9.0 |
% |
Antiproliferative activity against human Bel-7402 cells assessed as inhibition rate at 10 uM incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| HepG2 |
Inhibition |
= |
20.0 |
% |
Antiproliferative activity against human HepG2 cells assessed as inhibition rate at 10 uM incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| Hep 3B2 |
Inhibition |
= |
21.0 |
% |
Antiproliferative activity against human Hep3B cells assessed as inhibition rate at 10 uM incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| Bel-7402 |
IC50 |
= |
66230.0 |
nM |
Antiproliferative activity against human Bel-7402 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| HepG2 |
IC50 |
= |
89500.0 |
nM |
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| Hep 3B2 |
IC50 |
= |
77550.0 |
nM |
Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay |
CHEMBL5154755 |
| Bel-7402 |
Activity |
= |
5.52 |
% |
Induction of cell cycle arrest in human Bel-7402 cells assessed as accumulation of cells in subG1 phase at 50 uM measured after 24 hrs by propidium iodide staining based flow cytometry (Rvb=2.15+/-0.70%) |
CHEMBL5154755 |
| Bel-7402 |
Activity |
|
|
|
Induction of apoptosis in human Bel-7402 cells assessed as increase in apoptotic cells at 50 uM for 24 hrs by TUNEL staining method |
CHEMBL5154755 |
| Bel-7402 |
T/C |
= |
56.1 |
% |
Antitumor activity against human Bel-7402 cells xenografted in BAlb/c (nu/nu) mouse assessed as T/C ratio at 40 mg/kg, po daily measured after 14 days |
CHEMBL5154755 |
| Bel-7402 |
Inhibition |
= |
44.56 |
% |
Antitumor activity against human Bel-7402 cells xenografted in BAlb/c (nu/nu) mouse assessed as inhibition rate at 40 mg/kg, po daily measured after 14 days |
CHEMBL5154755 |
| Bel-7402 |
Activity |
= |
0.32 |
g |
Antitumor activity against human Bel-7402 cells xenografted in Balb/c (nu/nu) mouse assessed as tumor weight at 40 mg/kg, po qd after 14 days (Rvb=0.65 +/- 0.06 g) |
CHEMBL5154755 |
| Bel-7402 |
Activity |
= |
14.41 |
|
Antitumor activity against human Bel-7402 cells xenografted in Balb/c (nu/nu) mouse assessed as relative tumor volume at 40 mg/kg, po qd after 14 days (Rvb=25.69+/-2.73 No_unit) |
CHEMBL5154755 |
| Bel-7402 |
Activity |
|
|
|
Induction of apoptosis in human Bel-7402 cells xenografted in Balb/c (nu/nu) mouse assessed as decrease in phosphorylation of Akt at serine 473 residue at 40 mg/kg, po daily after 14 days by western blot analysis |
CHEMBL5154755 |
| Bel-7402 |
Activity |
|
|
|
Induction of apoptosis in human Bel-7402 cells xenografted in Balb/c (nu/nu) mouse assessed as increase in expression of cleaved PARP at 40 mg/kg, po daily after 14 days by western blot analysis |
CHEMBL5154755 |
| Bel-7402 |
Activity |
|
|
|
Induction of apoptosis in human Bel-7402 cells xenografted in Balb/c (nu/nu) mouse assessed as increase in expression of cleaved caspase-3 at 40 mg/kg, po daily after 14 days by western blot analysis |
CHEMBL5154755 |
| PI3-kinase p110-delta subunit |
IC50 |
= |
7.0 |
nM |
Inhibition of PI3Kdelta (unknown origin) measured by ADP-Glo assay |
CHEMBL5214954 |
| Histone deacetylase 6 |
IC50 |
|
|
|
Inhibition of HDAC6 (unknown origin) measured by fluorescence based assay |
CHEMBL5214954 |
| Histone deacetylase 1 |
IC50 |
|
|
|
Inhibition of HDAC1 (unknown origin) measured by fluorescence based assay |
CHEMBL5214954 |
| KM12 |
IC50 |
= |
960.0 |
nM |
Antiproliferative activity against human KM12 cells incubated for 72 hrs by CCK-8 assay |
CHEMBL5214954 |
| HCT-116 |
IC50 |
= |
2960.0 |
nM |
Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CCK-8 assay |
CHEMBL5214954 |
| T47D |
IC50 |
= |
510.0 |
nM |
Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK-8 assay |
CHEMBL5214954 |
| SU-DHL-6 |
IC50 |
= |
53.0 |
nM |
Antiproliferative activity against human SU-DHL-6 cells incubated for 72 hrs by CCK-8 assay |
CHEMBL5214954 |
| HUVEC |
IC50 |
= |
38220.0 |
nM |
Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay |
CHEMBL5214954 |
| PI3-kinase p110-alpha subunit |
IC50 |
= |
467.0 |
nM |
Inhibition of PI3Kalpha (unknown origin) measured by ADP-Glo assay |
CHEMBL5214954 |
| PI3-kinase p110-gamma subunit |
IC50 |
= |
50.5 |
nM |
Inhibition of PI3Kgamma (unknown origin) measured by ADP-Glo assay |
CHEMBL5214954 |
| Unchecked |
Ratio IC50 |
= |
67.0 |
|
Selectivity ratio, ratio IC50 for inhibition of PI3Kalpha (unknown origin) to IC50 for inhibition of PI3Kdelta (unknown origin) |
CHEMBL5214954 |
| Unchecked |
Ratio IC50 |
= |
7.2 |
|
Selectivity ratio, ratio IC50 for inhibition of PI3Kgamma (unknown origin) to IC50 for inhibition of PI3Kdelta (unknown origin) |
CHEMBL5214954 |
